Cognitive function testing: The case for standardization and automation

Journal of the British Menopause Society

Volumn 12, Issue 4, 2006, Pages 158-163

  Wesnes, Keith A ^a,b  

^a Cognitive Drug Research Ltd ^*  (United Kingdom)

^b NORTHUMBRIA UNIVERSITY   (United Kingdom)

Author keywords

Ageing; Cognition; Cognitive testing; Dementia; Stroke

Indexed keywords

2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; ARMODAFINIL; CHOLINESTERASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTRADIOL; FENTANYL; GALANTAMINE; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; GUARANA EXTRACT; NICOTINIC AGENT; NOOTROPIC AGENT; PLACEBO; PLANT EXTRACT; REBOXETINE; RIVASTIGMINE; SAGE EXTRACT; SCOPOLAMINE; UNCLASSIFIED DRUG;

AGING; ATTENTION; ATTENTION DEFICIT DISORDER; AUTOMATION; CANCER PAIN; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COGNITIVE DEFECT; CORRELATION ANALYSIS; DAILY LIFE ACTIVITY; DEMENTIA; DEPRESSION; DISEASE CLASSIFICATION; DRUG MECHANISM; ELDERLY CARE; EVIDENCE BASED MEDICINE; GUARANA; HERBAL MEDICINE; HUMAN; HYPERTENSION; MEDICINAL PLANT; MEMORY DISORDER; MENTAL DETERIORATION; MENTAL FUNCTION; MENTAL TEST; MINI MENTAL STATE EXAMINATION; NARCOLEPSY; PARKINSON DISEASE; REVIEW; SAGE; SLEEP APNEA SYNDROME; STANDARDIZATION; SYSTEMATIC REVIEW; TREATMENT FAILURE; WECHSLER MEMORY SCALE; WORKING MEMORY;

ACTIVITIES OF DAILY LIVING; AGING; CEREBROVASCULAR ACCIDENT; COGNITION; COGNITION DISORDERS; DEMENTIA; DIAGNOSIS, COMPUTER-ASSISTED; HUMANS; HYPERTENSION; PSYCHOLOGICAL TESTS;

EID: 33845873845     PISSN: 13621807     EISSN: 17404568     Source Type: Journal    
DOI: 10.1258/136218006779160544     Document Type: Review

References (41)

1. Barber B, Daley S, O'Brien J. Dementia. In: Keith L, Rees M, Mander T, eds. Menopause, Postmenopause and Ageing. London: Royal Society of Medicine Press, 2005: 20-34
2. Wesnes KA, Hildebrand K, Mohr E. Computerised cognitive assessment. In: Wilcock GW, Bucks RS, Rocked K, eds. Diagnosis and Management of Dementia: A Manual for Memory Disorders Teams. Oxford: Oxford University Press, 1999: 124-36
3. Wesnes K, Pincock C. Practice effects on cognitive tasks: a major problem? Lancet Neurol 2002;1:473
4. Levy R. Aging-associated cognitive decline. Int Psychogeriatr 1994;6:63-8
5. Simpson PM, Surmon DJ, Wesnes KA, Wilcock GK. The Cognitive Drug Research computerised assessment system for demented patients: a validation study. Int J Geriatr Psychiatry 1991;6:95-102
6. Nicholl CG, Lynch S, Kelly CA, et al. The Cognitive Drug Research computerised assessment system in the evaluation of early dementia - is speed of the essence? Int J Geriatr Psychiatry 1995;10:199-206
7. Mohr E, Walker D, Randolph C, et al. The utility of clinical trial batteries in the measurement of Alzheimer's and Huntington's dementia. Int Psychogeriatr 1996;8:397-411
8. Walker MP, Ayre GA, Cummings J L, et al. Quantifying fluctuation in dementia with Lewy bodies, Alzheimer's disease and vascular dementia. Neurology 2000;54:1616-25
9. Zaffalon M, Wesnes K, Petrini O. Reliable diagnosis of dementia by the naïve credal classifier inferred from incomplete cognitive data. Artif Intell Med 2003;29:61-79
10. Corani G, Edgar U, Marshall I, et al. Classification of dementia types from cognitive profiles data. In: Proceedings of 10th European Conference on Principles and Practice of Knowledge Discovery in Databases. Berlin: Springer-Verlag (in press)
11. Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 2005;4:487-99
12. Harrington F, Saxby BK, McKeith IG, et al. Cognitive performance in hypertensive and normotensive older subjects. Hypertension 2000;36:1079-82
13. Censori B, Manara O, Agostinis C, et al. Dementia after first stroke. Stroke 1996;27:1205-10
14. Ballard C, Stephens S, Kenny RA, et al. Profile of neuro-psychological deficits in older stroke survivors without dementia. Dement Geriatr Cogn Disord 2002;16:52-6
15. DeCarli C, Murphy DG, Tranh M, et al. The effect of white matter hyperintensity volume on brain structure, cognitive performance, and cerebral metabolism of glucose in 51 healthy adults. Neurology 1995;45:2077-84
16. Burton EJ, Kenny RA, O'Brien J, et al. White matter hyper-intensities are associated with impairment of memory, attention and global cognitive performance in older stroke patients. Stroke 2004;35:1270-5
17. Vellas B, Cunha L, Gertz HJ, et al. Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease. Curr Med Res Opin 2005;21:1423-9
18. Stephens S, Kenny R, Rowan E, et al. Association between mild vascular cognitive impairment and impaired activities of daily living in older (>75) stroke survivors without dementia. J Am Geriatr Soc 2005; 53:103-7
19. Ballard CG, Walker M, O'Brien J, et al. The characterisation and impact of 'fluctuating' cognition in dementia with Lewy bodies and Alzheimer's disease. Int J Geriatr Psychiatry 2001;16:494-8
20. Bronnick K, Ehrt U, Emre M, et al. Attentional deficits affect activities of daily living in dementia associated with PD. J Neurol Neurosurg Psychiatry 2006; Epub ahead of print
21. Wesnes KA, Zangara A, Scholey A, Kennedy D. Natural products as cognition enhancing agents. In: Buccafusco JJ, ed. Cognition Enhancing Drugs. Basel: Birkhauser Verlag, 2004: 151-78
22. Wesnes K, Simmons D, Rook M, Simpson PM. A double blind placebo controlled trial of tanakan in the treatment of idiopathic cognitive impairment in the elderly. Hum Psychopharmacol 1987; 2:159-69
23. Wesnes KA, Ward T, McGinty A, Petrini O. The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle aged volunteers. Psychopharmacol 2000;152: 353-61
24. Kennedy DO, Haskell CF, Wesnes KA, Scholey AB. Improved cognitive performance following acute administration of guarana (Paullinia cupana) containing low levels of caffeine: comparison and interaction with Panax ginseng. Pharmacol Biochem Behav 2004;79:401-11
25. Tildesley NTJ, Kennedy DO, Perry EK, et al. Salvia lavandulae-folia (Spanish sage) enhances memory in healthy young volunteers. Pharmacol Biochem Behav 2003;75:669-74
26. Wesnes K, Luthringer R, Ambrosetti C, et al. The effects of a combination of Panax ginseng, vitamins and minerals on mental performance, mood and physical fatigue in nurses working night shifts: a double blind, placebo-controlled trial. Curr Topics Nutraceutical Res 2003;1:169-74
27. Ferguson J, Wesnes K, Schwartz G. Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. Int Clin Psychopharmacol 2003;18:1-6
28. Harsh JR, Hayduk R, Rosenberg R, et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin 2006;22:761-74
29. Roth T, White D, Schmidt-Nowara W, et al. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week multicentre, double-blind, randomised, placebo-controlled study in nCPAP-adherent adults. Clin Ther 2006; 28:689-706
30. Wilens TE, Verlinden MH, Adler LA, et al. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/ hyperactivity disorder in adults: results of a pilot study. Biol Psychiatry 2006 (in press)
31. Hearing S, Wesnes K, Bowman C. Beta-blockers and cognitive function in elderly hypertensive patients: withdrawal and consequences of ACE inhibitor substitution. Int J Geriatr Psychopharmacol 1999;2:13-17
32. McNamara. Opioid switching from morphine to transdermal fentanyl for toxicity reduction in palliative care. Palliat Med 2002;16:425-34
33. Blacker CVR, Greenwood D, Wesnes K, et al. Effect of galantamine hydrobromide in chronic fatigue syndrome: a randomised controlled trial. JAMA 2004;292:1195-204
34. Allain H, Neuman E, Malbezin M, et al. Bridging study of S12024 in 53 in-patients with Alzheimer's disease. J Am Geriatr Soc 1997;45:125-6
35. Siegfried KR. The pharmacodynamics of velnacrine: results and conclusions from clinical studies in healthy subjects and patients with Alzheimer's disease. In: Wilcock GK, ed. The Management of Alzheimer's Disease. Petersfield: Wrightson Biomedical Publishing, 1993: 189-201
36. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031-6
37. Wesnes KA, McKeith IG, Ferrara R, et al. Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomised placebo-controlled international study using the Cognitive Drug Research computerised assessment system. Dement Geriatr Cogn Disord 2002;13:183-92
38. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-18
39. Wesnes KA, McKeith IG, Edgar C, et al. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 2005;65:1654-6
40. Schiff R, Bulpitt CJ, Wesnes KA, Rajkumar C. Short term transdermal estradiol therapy, cognition and depressive symptoms in healthy older women. A randomised placebo controlled pilot cross-over study. Psychoneuroendocrinol 2004;30:309-15
41. Bartholomeusz CF, Kulkarni J, Wesnes K, et al. Are the effects of estrogen on cognition mediated via modulation of the cholinergic system? Paper presented at Collegium International Neuro-Psychopharmacologicum, Chicago, July 2006